The Head of the Local American Working Group (LAWG), Rūta Pumputienė, has written a commentary about the costs of medicine and about how being stingy always means paying twice. It was published on the news website DELFI.
“Lithuanians love to talk about being a good site for the Life Sciences: according to the data of Enterprise Lithuania, the Life Sciences sector is one of the most dynamic, reaching as much 25% in annual growth,” begins the commentary by R. Pumputienė.
However, she reveals how the state is losing so much more by not providing enough innovative medicines to its citizens.
“Lithuania is lacking the sufficient availability of innovative medicines, and patients are deprived of the right to control or even to be cured from a disease or its indications, as well as being denied better health outcomes, shorter treatment times, greater safety (fewer side effects, better medicine tolerance), better interactions with other drugs, and other benefits,” noted R. Pumputienė.